Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life.

Cappello C, Tremolaterra F, Pascariello A, Ciacci C, Iovino P.

Int J Colorectal Dis. 2013 Mar;28(3):349-58. doi: 10.1007/s00384-012-1552-1.

2.

A pilot study on the effect of a symbiotic mixture in irritable bowel syndrome: an open-label, partially controlled, 6-month extension of a previously published trial.

Bucci C, Tremolaterra F, Gallotta S, Fortunato A, Cappello C, Ciacci C, Iovino P.

Tech Coloproctol. 2014 Apr;18(4):345-53. doi: 10.1007/s10151-013-1055-2.

PMID:
23922211
3.

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.

Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR.

Neurogastroenterol Motil. 2005 Oct;17(5):687-96.

4.

Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Didari T, Mozaffari S, Nikfar S, Abdollahi M.

World J Gastroenterol. 2015 Mar 14;21(10):3072-84. doi: 10.3748/wjg.v21.i10.3072. Review.

5.

Effectiveness of probiotics in the treatment of irritable bowel syndrome.

Wilhelm SM, Brubaker CM, Varcak EA, Kale-Pradhan PB.

Pharmacotherapy. 2008 Apr;28(4):496-505. doi: 10.1592/phco.28.4.496. Review.

PMID:
18363533
6.

A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.

Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD.

BMC Gastroenterol. 2013 Mar 7;13:45. doi: 10.1186/1471-230X-13-45.

7.

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.

Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR.

Aliment Pharmacol Ther. 2003 Apr 1;17(7):895-904.

8.

Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.

Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P.

J Gastroenterol Hepatol. 2007 Aug;22(8):1183-9.

PMID:
17688659
9.
10.

Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil.

Chiba T, Kudara N, Sato M, Chishima R, Abiko Y, Inomata M, Orii S, Suzuki K.

Hepatogastroenterology. 2005 Sep-Oct;52(65):1416-20.

PMID:
16201086
11.

The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.

Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.

J Clin Gastroenterol. 2012 Mar;46(3):220-7. doi: 10.1097/MCG.0b013e31823712b1.

PMID:
22157240
12.

Colonic transit time and IBS symptoms: what's the link?

Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M.

Am J Gastroenterol. 2012 May;107(5):754-60. doi: 10.1038/ajg.2012.5.

PMID:
22334251
13.

Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.

Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006.

14.

Does oral α-galactosidase relieve irritable bowel symptoms?

Hillilä M, Färkkilä MA, Sipponen T, Rajala J, Koskenpato J.

Scand J Gastroenterol. 2016 Jan;51(1):16-21. doi: 10.3109/00365521.2015.1063156.

PMID:
26133538
15.

Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome.

Cash BD.

Curr Med Res Opin. 2014 Jul;30(7):1405-15. doi: 10.1185/03007995.2014.908278. Review.

PMID:
24666019
16.

Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.

Camilleri M, Vazquez-Roque M, Iturrino J, Boldingh A, Burton D, McKinzie S, Wong BS, Rao AS, Kenny E, Månsson M, Zinsmeister AR.

Am J Physiol Gastrointest Liver Physiol. 2012 Jul;303(1):G120-8. doi: 10.1152/ajpgi.00076.2012.

18.

Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.

Guglielmetti S, Mora D, Gschwender M, Popp K.

Aliment Pharmacol Ther. 2011 May;33(10):1123-32. doi: 10.1111/j.1365-2036.2011.04633.x.

19.

Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.

Chmielewska-Wilkoń D, Reggiardo G, Egan CG.

World J Gastroenterol. 2014 Sep 14;20(34):12283-91. doi: 10.3748/wjg.v20.i34.12283.

20.

Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.

Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC.

Scand J Gastroenterol. 2012 Oct;47(10):1159-64.

PMID:
22783919

Supplemental Content

Support Center